Contents

Current Drug Targets, Volume 15 - Number 2

The First Approved Agent in the Glitazar’s Class: Saroglitazar

, 15(2): 151 - 155

Ritesh Agrawal


DOI: 10.2174/13894501113149990199




Communication Factors-Promising Targets in Osteoporosis Treatment

, 15(2): 156 - 163

Yan Zhang, Peijun Liu, Juan Li, Kun Li, Yue Teng, Xiang Wang and Xu Li


DOI: 10.2174/13894501113149990200




Inducible Nitric Oxide Synthase as a Possible Target in Hypertension

, 15(2): 164 - 174

Gustavo H. Oliveira-Paula, Riccardo Lacchini and Jose E. Tanus-Santos


DOI: 10.2174/13894501113146660227




The Medicinal Potential of Natural Products for the Development of Anti- Influenza Agents

, 15(2): 175 - 183

Fudong Sun and Ruiqin Huang


DOI: 10.2174/13894501113146660203




A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem

, 15(2): 184 - 198

Karunanidhi Priyanka and Sanjay Singh


DOI: 10.2174/1389450115666140113100338




Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism

, 15(2): 199 - 209

Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. Macaulay


DOI: 10.2174/13894501113146660226




Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives

, 15(2): 210 - 253

Arunachalam Muthuraman, Nirmal Singh, Amteshwar Singh Jaggi and Muthusamy Ramesh


DOI: 10.2174/1389210200418434501




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science